Divis Laboratories Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/z86oqbi4entg62wc8fcl40ib.pdf

Key Takeaways


Custom Synthesis: The Growth Engine

Dr. Kiran S. Divi: "So right now, strategically, what we have done is, we have emptied Unit 1 and Unit 2 with all the key starting materials and moved it to Kakinada Unit 3, so that we have GMP space immediately available for our immediate growth."

Kakinada Unit 3: Capacity Unlocked, Revenue Delayed

Dr. Kiran S. Divi: "While that is being done, certain long forward-looking products, which are getting off patent much later, we are qualifying them in Kakinada and then we will start the process, which will take at least 1 to 2 years before we have regulatory approvals in place for Kakinada."

Peptides & New Capabilities

Dr. Kiran S. Divi: "I would -- again, our wishful thinking is 12 to 14 months. It all depends on the regulatory approvals. And then, I mean, we being a part of the innovator, it's based on his time line on getting the product commercialized."

Generics: Pricing Pressure and Portfolio Resilience

Nilima Prasad Divi: "We are hoping that they would stabilize over the next few quarters."

Margins, Costs & Operating Model

Dr. Kiran S. Divi: "And this has become a part of our DNA where we look at atom-to-atom efficiency and try to understand every mole of waste that we produce, on why the byproducts are being produced, thereby increasing our yield, capacity and better product."

Guidance & Commitments

CommitmentSpecificsTimeline
Capex spend₹2,000 crores directed at strategic projects, capacity expansion, and technology upgradesFY26
Custom synthesis pipeline conversionSeveral active projects transition to commercial scaleNext 12 to 24 months
Three dedicated CS units commercializationProjects backed by long-term volume commitments go liveNext 12-month odd period
Generic product pipelineBrivaracetam, Ticagrelor and others begin commercial volumesNext 6 to 12 months
Kakinada regulatory approvalsGMP approvals for forward-looking products qualified at Unit 3At least 1 to 2 years
Generic/Custom Synthesis mixMaintain at 50% each for the full yearFY26
Pricing pressure stabilizationHoping pressures stabilizeNext few quarters

Key Metrics

MetricQ1 FY26
Consolidated total income₹2,529 cr, vs ₹2,197 cr in Q1 FY25
Standalone total income₹2,476 cr, vs ₹2,142 cr in Q1 FY25
Consolidated profit before tax₹733 cr, vs ₹604 cr in Q1 FY25
Consolidated profit after tax₹545 cr, vs ₹430 cr in Q1 FY25
Standalone profit before tax₹747 cr, vs ₹603 cr in Q1 FY25
Standalone profit after tax₹557 cr, vs ₹430 cr in Q1 FY25
Material consumption~40% of sales revenue, flat YoY
Constant currency growth14%
Forex gain₹39 cr gain, vs ₹1 cr loss in Q1 FY25
Exports share88% of total income; Europe 58%, US 14%
Product mixGenerics 47%, Custom Synthesis 53%
Nutraceutical business revenue₹250 cr, vs ₹178 cr in Q1 FY25
Capacity utilization80%, consistent over the last 1 year
Estimated capex for FY26₹2,000 cr
Assets capitalized during the quarter₹261 cr, of which Kakinada Phase 1: ₹114 cr
Capital work in progress₹1,319 cr at quarter end
Cash on books₹4,205 cr at quarter end
Receivables₹2,521 cr at quarter end
Inventory₹3,087 cr at quarter end